Targeting AhR Bayer Anti-Tumor Class 1 new drugs has been approved clinically in China

On December 17, Bayer obtained two clinical trials for the development of advanced malignant solid tumors with two clinical trials of BAY 2416964 tablets submitted in category 1 of chemicals, according to the Drug Review Center (CDE) of the State Drug Administration of China.
public information, BAY 2416964 is a highly selective aromatic hydrocarbon reorbent (AhR) inhibitor that is currently in its early stages of development worldwide.
screenshot source: CDE official website aromatic hydrocarbons (AhR) is a protein in immune cells, it can be based on the body's microorganisms, amino acid metabolism and other integrated signals to play an immunomodulation role.
because AhR is highly expressed in a variety of tumors and has immunomodulation, the regulator targeted at AhR is considered to be one of the new immunotherapy categories.
, these treatments are also expected to be used in combination with other drug categories to improve treatment effectiveness.
public information shows that BAY 2416964 is a powerful, selective and cross-reactive AhR inhibitor that can play a variety of anti-tumor immunomodulation effects.
it is able to block CYP1A1 transcriptions mediated by different AhR astrative mediators, and can interact directly with AhR, as well as inhibit the transport of the mating body induced to the nucleation of the cell.
studies have shown that BAY 2416964, with different doses and frequency of dosing, inhibits specific tumor models.
bay 2416964 human dose exploration study in patients with advanced cancer, according to the official website of Clinicaltrials.gov.
This is an open-label, Phase 1, first dose increment and extension study conducted in humans to assess the safety, tolerance, maximum tomic dosage, pharmacodynamics, pharmacodynamics, and tumor response profiles of ahR inhibitors BAY 2416964.
the study was launched in August 2019 and is scheduled to be completed in 2023.
photo source: Clinicaltrials.gov Website In China, Bayer submitted a clinical application for BAY 2416964 tablets in October this year and received CDE.
the first clinical approval of the product in China, which also means that the drug candidate will soon be in China's patients with advanced malignant tumors clinical research.
that the follow-up clinical development of this product is progressing smoothly and will bring a new treatment option to cancer patients at an early time.
References: China's State Drug Administration Drug Review Center. Retrieved Dec 17, 2020, from smh.com.au